Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses: 2023-2025

Historic Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $4.1 million.

  • Contineum Therapeutics' Accumulated Expenses rose 7.90% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 7.90%. This contributed to the annual value of $6.7 million for FY2024, which is 53.04% up from last year.
  • As of Q3 2025, Contineum Therapeutics' Accumulated Expenses stood at $4.1 million, which was up 9.37% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Accumulated Expenses ranged from a high of $6.7 million in Q4 2024 and a low of $2.5 million during Q2 2024.
  • For the 3-year period, Contineum Therapeutics' Accumulated Expenses averaged around $4.3 million, with its median value being $4.0 million (2025).
  • Per our database at Business Quant, Contineum Therapeutics' Accumulated Expenses spiked by 53.04% in 2024 and then dropped by 25.84% in 2025.
  • Contineum Therapeutics' Accumulated Expenses (Quarterly) stood at $4.4 million in 2023, then skyrocketed by 53.04% to $6.7 million in 2024, then climbed by 7.90% to $4.1 million in 2025.
  • Its Accumulated Expenses was $4.1 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.8 million in Q1 2025.